F-fludeoxyglucose positron emission tomography/CT scans and brain MRIs after achieving a complete metabolic response with rituximab.
CASE REPORT
A 42-year-old female with a history of systemic lupus erythematosus diagnosed at age 16 years (treated with azathioprine, cyclophosphamide and prednisone) and a renal transplant owing to lupus nephritis at age 30 years (treated with mycophenolate mofetil) presented with sudden onset of confusion and difficulty finding words. Contrast-enhanced MRI of the brain revealed two enhancing brain lesions (Figure 1 ), and the patient was referred for F-FDG-avid lung lesions with a maximum standardized uptake value of 12.1 (Figures 2  and 3 ), which were confirmed to be Grade 3/3 lymphomatoid granulomatosis (LYG) on lung wedge biopsy ( Figure 4) [certain nodules showed >100 Epstein-Barr virus (EBV)-encoded RNA-positive cells per high power field, Figure 5 ]. There was also intense focal 18 F-FDG uptake in the distal oesophagus with a maximum standardized uptake value of 8.5, which prompted a gastroscopy and biopsy, revealing an EBV-positive oesophageal ulcer that was treated with long-term valganciclovir 450 mg by mouth daily. She was treated with 4 weekly cycles of rituximab. A follow-up PET/ CT scan performed 4 weeks after completion of rituximab showed complete metabolic resolution of LYG lung lesions as well as the EBV oesophageal ulcer (Figure 6 ), and a follow-up MRI revealed complete resolution of the brain lesions ( Figure 7 ). Surveillance PET/CT ( Figure 8 ) and MRI ( Figure 9 ) studies performed 12 months later confirmed disease remission.
DISCUSSION
LYG is an EBV-related lymphoproliferative disorder characterized by an angiocentric and angiodestructive infiltration of the lungs, nervous system and skin with a polymorphous infiltrate of lymphocytes, plasma cells, histiocytes and atypical lymphoreticular cells. While the pathogenesis of LYG remains unknown, some investigators consider LYG as a neoplastic B-cell process correlated to EBV antigen stimulation, as EBV has been found in most cases of LYG. 1 At onset, most patients are between the ages of 30-50 years, with a predominance of males to females of 6-7 to 1.
2 Patients are often immunocompromised. LYG predominantly involves the lungs, and extrapulmonary involvement is seen in the skin (39%) and the central nervous system (CNS; 30%), and can be associated with splenomegaly, hepatomegaly or lymphadenopathy. 3 Patients can present with cough, shortness of breath, chest pain and B symptoms (fever, weight loss, malaise). Lung nodules are present in up to 80% of cases. In most cases, the lung nodules are irregular but well defined. They tend to be distributed along the bronchovascular bundles or interlobular septa, which can be explained by the angiocentric distribution of LYG. The differential diagnosis of the CT scan findings in the lungs includes pseudolymphoma, malignant lymphoma, lymphocytic interstitial pneumonia, metastasis, sarcoidosis, Wegener's granulomatosis and cryptogenic organizing pneumonia. 13 The most common CNS findings of LYG on MRI scans are multiple focal intraparenchymal lesions with high signal intensity on T 2 weighted images and punctate and/or linear enhancement, which seems to be a characteristic finding of LYG in the brain and corresponds to known perivascular and vascular wall infiltration by lymphoid cells.
14 EBV is most prevalent in Grade 3/3 lesions compared with Grade 1 or 2, and although the natural course of Grade 3 disease is extremely variable, prognosis is poor and mortality is very high. Katzenstein et al 3 found that 63.5% of 152 patients with LYG died within 36 months owing to destruction of pulmonary parenchyma, sepsis, massive haemoptysis or CNS disorders. Approximately 12% of LYG patients also develop malignant lymphoma. 3 Experimental treatment options for LYG have included corticosteroids, antiviral therapy, interferon-a and chemotherapy. The best results described in the literature have been reported with rituximab, an anti-CD20 monoclonal antibody. The rationale for the use of rituximab is the expression of CD20 on lymphoid cells of LYG lesions and the well-documented efficacy of rituximab in other CD20-positive lymphomas. 15 Several studies have now shown that CNS LYG lesions also respond to rituximab, as approximately 1% of administered rituximab can pass through the blood-brain barrier. 
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